Product Description
ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15468604/)
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lymphoma, Non-Hodgkin|Renal Cell Carcinoma|Head and Neck Cancer|Melanoma|Sarcoma|Non-Small-Cell Lung Cancer
Phase 1: Brain Cancer|Glioblastoma|Ischemic Attack, Transient|Hypertension, Renal|Myocardial Infarction|Edema|Skin Cancer|Constipation|Low Back Pain|Diarrhea|Dyspnea|Small Cell Lung Cancer|Angina, Stable|Headache|Peripheral Arterial Disease|Colorectal Cancer|Vascular Cancer|Ovarian Cancer|Anorexia|Dizziness|Glioma|Insomnia|Anemia|Abdominal Pain|Angina, Unstable|Breast Cancer|Asthenia|Chest Pain|Non-Small-Cell Lung Cancer|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Pro00008797 | P1 |
Completed |
Constipation|Skin Cancer|Asthenia|Peripheral Arterial Disease|Diarrhea|Low Back Pain|Chest Pain|Hypertension, Renal|Breast Cancer|Dizziness|Angina, Unstable|Kidney Diseases|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Insomnia|Edema|Ischemic Attack, Transient|Myocardial Infarction|Abdominal Pain|Angina, Stable|Headache|Colorectal Cancer|Anorexia|Anemia|Glioma|Dyspnea|Ovarian Cancer|Vascular Cancer |
2013-02-01 |
|
UAB 0327 | P1 |
Completed |
Glioblastoma|Brain Cancer |
2008-07-01 |
|
NCT00113334 | P2 |
Completed |
Head and Neck Cancer |
2008-03-01 |
|
CDR0000582475 | P2 |
Completed |
Melanoma |
2005-06-01 |